Clinical and pathological correlation of increased MYC gene copy number in diffuse large B-cell lymphoma (DLBCL)

Comparison of cases of DLBCL with increased copy number of MYC to those without MYC aberration demonstrated no significant difference in survival (p=0.58) for patients treated with Rituximab based regimens.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 20, 2016 Category: Hematology Authors: Bryn T. Haws, Wei Cui, Diane L. Persons, Da Zhang Tags: Original Study Source Type: research